A Moment of Convergence for Patients with Type-2 Diabetes

WRITTEN BY

Dr. Danilo Verge Vice President, Global Medical Affairs, CVRM, AstraZeneca

Our Cardiovascular Renal Metabolic (CVRM) therapy area has been asking hard questions for years – why does type-2 diabetes and its cardiovascular (CV) and renal complications continue to represent a global health crisis at a time when there are viable treatment options? What can be done to overcome obstacles to clinical inertia and treating these conditions more holistically? To help answer these questions and others, we are endeavouring to advance science from our extensive clinical programmes, while working alongside leading academic and health economic research groups.

The American Heart Association (AHA) Scientific Sessions 2018 in Chicago, USA, is a moment of convergence for this research, when answers are coming together for clinicians, payors and the patients who are at the centre of what we do.

The Need for Change

With the alarming rise of diabetes, we are facing one of the biggest global health crises of the 21st century.i In 2017, 4 million deaths globally were estimated to have happened because of diabetes and its complications.ii Of all these, CV complications, and more specifically heart failure, have a significant impact on patients and health systems alike.iii, iv Heart failure occurs relatively early in the disease progression of patients with type-2 diabetes, so it can result in extended and intense care including hospitalisations that result in a considerable cost burden on health systems.iii To help ensure a greater understanding of the need for patients to have access to innovative medicines that address T2D and CVD together,  we have partnered with Health Economics Outcomes Research (HEOR) Ltd to demonstrate the actual economic value of this approach for health systems and improved patient care.

Innovative Developments

At the 2018 AHA Scientific Sessions we will be presenting pivotal clinical data examining the effectiveness, safety profile and tolerability of treatments for patients with T2D, heart failure and renal disease, shedding light on the potential value of a CaReMe treatment approach when it is begun early in the management of the disease.

The Call to Action

As part of the global coalition of diabetes experts, Early Action in Diabetes (EAiD), we have partnered with Primary Care Diabetes Europe (PCDE) to study the perceptions and practices of healthcare professionals in Europe to better understand reasons for clinical inertia, or the lack of appropriate targets and escalation of treatments to achieve clinical goals. PCDE has shared this Call to Action to challenge primary care physicians and other healthcare providers to take specific steps to help tackle this clinical inertia. Specifically, the Call to Action will include greater compliance with treatment guidelines on earlier use of innovative treatments and greater collaboration with patients and other members of their health team to accelerate holistic care.

We are learning more everyday about how to overcome treatment and access obstacles, and how valuable it can be to treat earlier and more holistically. We are now bringing these insights together so that we can help HCPs drive meaningful change in treatment outcomes for patients with T2D.

 

i Chan, Margaret Dr, World Health Organisation, Director-General’s speech made at the 47th Meeting of the National Academy on Medicine, October 2016. Available at: http://www.who.int/dg/speeches/2016/obesity-diabetes-disaster/en/. Last accessed: June 2018.

ii International Diabetes Federation, IDF Diabetes Atlas, Eight Edition Update, 2017.

iii Faden, et al. The increasing detection of asymptomatic left ventricular dysfunction in patients with type 2 diabetes mellitus without overt cardiac disease: Data from the SHORTWAVE study. Diabetes Research and Clinical Practice. 2013.

iv Value Health. 2018 Jul;21(7):881-890. doi: 10.1016/j.jval.2017.12.019. Epub 2018 Feb 16.

 

Veeva ID: Z4-13608
Date of next review: October 2020